2022
Wearables in Cardiovascular Disease
Kumar S, Victoria-Castro AM, Melchinger H, O’Connor K, Psotka M, Desai NR, Ahmad T, Wilson FP. Wearables in Cardiovascular Disease. Journal Of Cardiovascular Translational Research 2022, 16: 557-568. PMID: 36085432, DOI: 10.1007/s12265-022-10314-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsRationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID)
Shah NN, Ghazi L, Yamamoto Y, Martin M, Simonov M, Riello RJ, Faridi KF, Ahmad T, Wilson FP, Desai NR. Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID). American Heart Journal 2022, 253: 76-85. PMID: 35841944, PMCID: PMC9936562, DOI: 10.1016/j.ahj.2022.07.002.Peer-Reviewed Original ResearchConceptsLipid-lowering therapyAtherosclerotic cardiovascular diseaseTreatment of hyperlipidemiaProportion of patientsElectronic health recordsPragmatic trialHigh riskCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsHigh-risk atherosclerotic cardiovascular diseaseSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol reductionImportant public health implicationsEnrollment of patientsPublic health implicationsUsual careSecondary outcomesPrimary outcomeGuideline recommendationsCholesterol reductionPatientsLDLHyperlipidemiaScalable interventionsOutpatients
2021
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes Insights From the EMPA-REG OUTCOME Trial
Sharma A, Ofstad AP, Ahmad T, Zinman B, Zwiener I, Fitchett D, Wanner C, George JT, Hantel S, Desai N, Mentz RJ. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes Insights From the EMPA-REG OUTCOME Trial. JACC Heart Failure 2021, 9: 568-577. PMID: 34325887, DOI: 10.1016/j.jchf.2021.03.003.Peer-Reviewed Original ResearchMeSH KeywordsCardiovascular DiseasesDiabetes Mellitus, Type 2Double-Blind MethodFemaleHeart FailureHumansPhenotypeSodium-Glucose Transporter 2 InhibitorsTreatment OutcomeConceptsCV deathLatent class analysisTreatment effectsNon-coronary artery diseaseEMPA-REG OUTCOME trialAdvanced coronary diseaseEMPA-REG OUTCOMESGLT-2 inhibitionGlomerular filtration rateType 2 diabetesEMPA-REGEmpagliflozin 25CV diseaseCV riskLower eGFRT2D durationOlder patientsOutcome trialsYounger patientsArtery diseaseCoronary diseaseCox regressionFiltration rateCardiovascular diseaseGroup 2Setting the Stage for a Multimarker-Based Heart Failure Prevention Trial? ∗
Ahmad T, Felker GM. Setting the Stage for a Multimarker-Based Heart Failure Prevention Trial? ∗. JACC Heart Failure 2021, 9: 224-225. PMID: 33632419, DOI: 10.1016/j.jchf.2021.01.001.Peer-Reviewed Original ResearchCardiovascular DiseasesDiabetes Mellitus, Type 2Heart FailureHumansSodium-Glucose Transporter 2 InhibitorsRelation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry)
Pareek M, Singh A, Vadlamani L, Eder M, Pacor J, Park J, Ghazizadeh Z, Heard A, Cruz-Solbes AS, Nikooie R, Gier C, Ahmed ZV, Freeman JV, Meadows J, Smolderen KGE, Lampert R, Velazquez EJ, Ahmad T, Desai NR. Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry). The American Journal Of Cardiology 2021, 146: 99-106. PMID: 33539857, PMCID: PMC7849530, DOI: 10.1016/j.amjcard.2021.01.029.Peer-Reviewed Original ResearchConceptsCardiovascular risk factorsCoronavirus disease 2019Risk factorsHigher troponin TCardiovascular diseaseCardiovascular eventsHospitalized patientsLaboratory findingsMental statusDisease 2019Multivariable binary logistic regression analysisTroponin TMajor adverse cardiovascular eventsPre-existing cardiovascular diseaseHigher C-reactive proteinCOVID-19 positive patientsPredictors of MACEPrevious ventricular arrhythmiaUse of P2YAdverse cardiovascular eventsProspective cohort studyTertiary care centerC-reactive proteinBinary logistic regression analysisPoor prognostic markerTransition From an Open to Closed Staffing Model in the Cardiac Intensive Care Unit Improves Clinical Outcomes
Miller PE, Chouairi F, Thomas A, Kunitomo Y, Aslam F, Canavan ME, Murphy C, Daggula K, Metkus T, Vallabhajosyula S, Carnicelli A, Katz JN, Desai NR, Ahmad T, Velazquez EJ, Brennan J. Transition From an Open to Closed Staffing Model in the Cardiac Intensive Care Unit Improves Clinical Outcomes. Journal Of The American Heart Association 2021, 10: e018182. PMID: 33412899, PMCID: PMC7955420, DOI: 10.1161/jaha.120.018182.Peer-Reviewed Original ResearchConceptsCardiac intensive care unitIntensive care unitHospital mortalityCare unitCICU mortalityClinical outcomesModern cardiac intensive care unitSurgical intensive care unitTotal hospital chargesSeverity of illnessMultivariable logistic regressionCICU lengthMultivariable adjustmentRespiratory insufficiencyPrimary outcomeUnique admissionsHospital chargesCardiac arrestSubgroup analysisImproved outcomesMortalityLogistic regressionAdmissionClosed unitStaffing models
2020
Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer
Angraal S, Caraballo C, Kahn P, Bhatnagar A, Singh B, Wilson FP, Fiuzat M, O'Connor CM, Allen LA, Desai NR, Mamtani R, Ahmad T. Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer. American Heart Journal 2020, 230: 54-58. PMID: 32950462, PMCID: PMC7734611, DOI: 10.1016/j.ahj.2020.08.014.Peer-Reviewed Original ResearchConceptsCardiovascular mortality ratesMortality rateCardiovascular mortalityCancer mortalityCardiovascular diseaseMedical CenterIndex groupAnnual cardiovascular mortality rateCardiovascular mortality trendsCancer mortality ratesAcademic medical centerBenefit of patientsMortality trendsSociodemographic characteristicsMortalityIncremental benefitComparison groupNIH fundingImplementation scienceNIHHigh rateDiseaseRapid translationAverage declineResearch priorities